Clinical trials
Astrocytoma clinical trials
Below are recruiting astrocytoma clinical trials, each written for real people, not researchers. We’re tracking 61 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07560865RecruitingPhase 1
New Cell Therapy for Recurring Brain Cancer
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
Minneapolis, MinnesotaAges 18–75 - NCT07544992RecruitingPhase 1
CAR T Cells for Recurrent High-Grade Brain Tumors
This trial tests genetically engineered immune cells (CAR T cells) injected directly into the brain to treat recurring or worsening high-grade gliomas. The cells are designed to recognize and attack tumor cells that have specific markers (EGFR and IL13Rα2).
Duarte, CaliforniaAges 18 years+ - NCT07215910RecruitingPhase 3
Testing vorasidenib with temozolomide after radiation for advanced brain cancer
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
Duarte, CaliforniaAges 12 years+ - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT03596086RecruitingPhase 1/Phase 2
Study drug plus radiation and chemo for recurrent brain cancer
This Phase 1/2 study tests whether combining an HSV-tk “gene switch” treatment, valacyclovir tablets, focused radiation (SBRT), and chemotherapy can help people with recurrent glioblastoma or anaplastic astrocytoma. It may help shrink tumors or slow growth after standard treatments have already been tried.
Houston, TexasAges 18 years+ - NCT03603405RecruitingPhase 1/Phase 2
Test vaccine and radiation with chemotherapy for new brain tumor
This trial studies a gene-based treatment (HSV-tk) given with radiation and chemotherapy for people newly diagnosed with glioblastoma or anaplastic astrocytoma. It may help the new brain tumor respond better to standard treatments, though risks and benefits are still being tested.
Houston, TexasAges 18 years+ - NCT03861299Recruiting
Awake brain surgery versus sleep surgery for glioblastoma
This study compares two ways of doing brain surgery for glioblastoma: doing parts of the operation while you are awake, versus doing it fully under general anesthesia (sleep). It aims to see which approach is safer and better for protecting brain functions like speech and movement while removing the tumor.
GhentAges 18–90 - NCT03896568RecruitingPhase 1
Trial of stem cell therapy for recurrent high-grade brain tumors
This Phase 1 study tests an advanced stem-cell treatment (hMSC-DNX2401) for recurrent high-grade glioma, including certain brain tumor types that come back. It aims to see if the treatment can be safely delivered and whether it can help control the tumor after standard therapies have already been tried.
Houston, TexasAges 18 years+ - NCT04648462Recruiting
Proton therapy planning for certain brain tumors
This study builds and tests how proton therapy planning could better protect the brain compared with standard radiation (photon therapy) for adults with certain brain tumors. It may help reduce radiation to sensitive areas like the hippocampus, with the goal of better long-term brain function.
Maastricht, LimburgAges 18 years+ - NCT04780009Recruiting
Imaging tool during brain tumor surgery
This trial tests a special camera system used during surgery to help doctors see brain tumor tissue using fluorescent light. It may help the surgeon remove more tumor while protecting healthy brain areas.
Lexington, KentuckyAges 18–90 - NCT05084430RecruitingPhase 1/Phase 2
Pembrolizumab plus M032 for recurrent brain tumors
This early-phase study tests the safety and early signs of benefit of combining pembrolizumab with M032 in people with certain aggressive brain tumors. You may be considered if you have a glioma tumor that can potentially be removed by surgery.
Birmingham, AlabamaAges 18 years+ - NCT05190172Recruiting
Proton versus photon radiation for IDH-mutated brain tumors
This trial compares two types of radiation—proton therapy versus photon (standard) therapy—for adults with an IDH-mutated grade 2 or 3 brain tumor. The goal is to see which approach works better and/or causes fewer side effects while treating the tumor.
OsloAges 18–65 - NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05683808RecruitingPhase 2
Apixaban to prevent blood clots in outpatient brain tumor patients
This trial tests whether apixaban, a blood thinner, can prevent dangerous blood clots in people with a certain type of malignant brain tumor who are getting radiation and chemotherapy. It may help lower the risk of clots like leg clots or lung clots.
Burlington, VermontAges 18 years+ - NCT05698524RecruitingPhase 1
Temodar plus an investigational pill for recurrent brain cancer
This Phase 1 study tests an investigational drug (PCI-24781) together with Temodar in people whose high-grade glioma (grade III/IV) has come back after prior treatment. It aims to find a safe dose and see how well the combination may work for recurrent disease.
Omaha, NebraskaAges 19 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
Chicago, IllinoisAges 18 years+ - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Aurora, ColoradoAges 1–39 - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Aurora, ColoradoAges 1–39 - NCT06273176Recruiting
Surgery with or without brain mapping for recurrent glioblastoma
This study is testing whether using a special brain-mapping technique during surgery helps people with recurrent glioblastoma. It compares standard surgery to surgery with mapping to see if it leads to better outcomes for tumors near important brain areas.
San Francisco, CaliforniaAges Up to 90 years - NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Aurora, ColoradoAges 1–21 - NCT06344130RecruitingPhase 1
Shorter radiation for recurrent glioblastoma
This trial tests a new, shorter course of radiation therapy (called hypofractionation) for people with glioblastoma that has come back. It is for patients who have already had radiation and are doing well enough to consider another round.
Bethesda, MarylandAges 18–120 - NCT06623565Recruiting
Advanced imaging for extensive brain tumor removal
This trial uses advanced imaging to help surgeons remove as much of a malignant brain tumor as safely possible. It may be a good fit if you have a new diagnosis of glioblastoma or a certain astrocytoma and are healthy enough for surgery.
Amsterdam, North HollandAges 18 years+ - NCT06630260RecruitingPhase 1/Phase 2
Avutometinib and Defactinib for brain tumors
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
CambridgeAges 16 years+ - NCT06632236RecruitingPhase 1
Amivantamab for advanced brain tumors
This trial tests a new drug called amivantamab for people with advanced brain tumors, including glioblastoma. It aims to see if the drug can shrink or slow tumor growth.
CambridgeAges 16 years+
Hear when a new Astrocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for astrocytoma?
- Yes. Clin2 currently lists 61 recruiting astrocytoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a astrocytoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a astrocytoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.